LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS

Abstract. Recurrent respiratory papillomatosis (RRP) is the most frequently occurring tumour of the upper airways associated with a human papilloma virus (HPV). The aim of this study was to reveal some features of systemic and local immunity in RRP, to investigate clinical and immunological efficien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Plouzhnikov, E. Katinas, M. Ryabova, S. Karpishenko, K. Syssoev, A. Chukhlovin, A. Totolian
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	recurrent papillomatosis local immunity immunotherapy recombinant interferon-α2 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/198ebee8cdc94eaf97af1418eb10420f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:198ebee8cdc94eaf97af1418eb10420f
record_format	dspace
spelling	oai:doaj.org-article:198ebee8cdc94eaf97af1418eb10420f2021-11-18T08:03:42ZLOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS1563-06252313-741X10.15789/1563-0625-2006-5-6-679-688https://doaj.org/article/198ebee8cdc94eaf97af1418eb10420f2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/571https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Recurrent respiratory papillomatosis (RRP) is the most frequently occurring tumour of the upper airways associated with a human papilloma virus (HPV). The aim of this study was to reveal some features of systemic and local immunity in RRP, to investigate clinical and immunological efficiency of local treatment with recombinant interferon-α (rIFNα), and to determine clinical and laboratory indications to it’s administration. The study included forty-one patients with confirmed RRP. Their examination included histological examination of papillomas, detection of HPV DNA in papilloma tissues using PCR technique, phenotyping of circulating lymphocytes (CD3+, CD4+, CD8+, CD25+, HLA-DR+) by means of flow cytometry. The levels of IFNγ, TNFα, GM-CSF, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 in laryngeal secretions were quantified by a multiplex immunoassay. In all cases, we revealed an initially decreased functional activity of Т-lymphocytes, as well as low contents of Т-killer and NK-cells. In laryngeal secretions, increased values of Th1-type-specific cytokines (IFNγ and TNFα) were found. Besides that, high levels of local IL-4 were detected thus being typical to alternative Th2-type response. Single inhalations 1000 000 ME of «Interal» or «Roferon» preparations were administered daily (a total of 10-15 millions ME per therapeutic course). Thirteen patients received the treatment after surgery, as an adjuvant therapy, and eleven patients underwent monotherapy. Complete tumor regression of tumors following this monotherapy was observed in 45,5% of the patients, whereas partial regression was registered in 45%. The effect was mostly expressed in frequently recurring juvenile papillomatosis with aggressive course and histological pattern of actively proliferating papilloma. In the patients with complete tumor regression, high initial levels of TNFα and IL-4/IFNг ratios were revealed initially in laryngeal secretions. When rIFNб was administered, an increase in Th1-type cytokines (IFNγ, IL-12, IL-2) and GM-CSF were revealed, as well as decrease of initially high levels of IL-10, like as lowered levels of IL-4 and IL-13. In cases of partial tumor regression, the levels of IFNα, IL-12, IL-2 and GM-CSF were decreased against initial values, and in the course of treatment they fluctuated within normal reference values. Cancellation of the therapy was followed by increase in IL-4 and IL-13 levels. Hence, the local rIFNα therapy is effective in controlling aggressive recurrent respiratory papillomatosis. Initial increase in TNFα and IL-4/IFNγ ratios in laryngeal secretions may be considered as favorable predictor of anticipated therapy, whereas increased levels of IFNα, IL-2 and IL-12 together with decrease (normalization) of IL-4/IFNγ ratio may reflect the efficiency of the treatment performed.M. PlouzhnikovE. KatinasM. RyabovaS. KarpishenkoK. SyssoevA. ChukhlovinA. TotolianSPb RAACIarticlerecurrent papillomatosislocal immunityimmunotherapyrecombinant interferon-α2Immunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 8, Iss 5-6, Pp 679-688 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	recurrent papillomatosis local immunity immunotherapy recombinant interferon-α2 Immunologic diseases. Allergy RC581-607
spellingShingle	recurrent papillomatosis local immunity immunotherapy recombinant interferon-α2 Immunologic diseases. Allergy RC581-607 M. Plouzhnikov E. Katinas M. Ryabova S. Karpishenko K. Syssoev A. Chukhlovin A. Totolian LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
description	Abstract. Recurrent respiratory papillomatosis (RRP) is the most frequently occurring tumour of the upper airways associated with a human papilloma virus (HPV). The aim of this study was to reveal some features of systemic and local immunity in RRP, to investigate clinical and immunological efficiency of local treatment with recombinant interferon-α (rIFNα), and to determine clinical and laboratory indications to it’s administration. The study included forty-one patients with confirmed RRP. Their examination included histological examination of papillomas, detection of HPV DNA in papilloma tissues using PCR technique, phenotyping of circulating lymphocytes (CD3+, CD4+, CD8+, CD25+, HLA-DR+) by means of flow cytometry. The levels of IFNγ, TNFα, GM-CSF, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 in laryngeal secretions were quantified by a multiplex immunoassay. In all cases, we revealed an initially decreased functional activity of Т-lymphocytes, as well as low contents of Т-killer and NK-cells. In laryngeal secretions, increased values of Th1-type-specific cytokines (IFNγ and TNFα) were found. Besides that, high levels of local IL-4 were detected thus being typical to alternative Th2-type response. Single inhalations 1000 000 ME of «Interal» or «Roferon» preparations were administered daily (a total of 10-15 millions ME per therapeutic course). Thirteen patients received the treatment after surgery, as an adjuvant therapy, and eleven patients underwent monotherapy. Complete tumor regression of tumors following this monotherapy was observed in 45,5% of the patients, whereas partial regression was registered in 45%. The effect was mostly expressed in frequently recurring juvenile papillomatosis with aggressive course and histological pattern of actively proliferating papilloma. In the patients with complete tumor regression, high initial levels of TNFα and IL-4/IFNг ratios were revealed initially in laryngeal secretions. When rIFNб was administered, an increase in Th1-type cytokines (IFNγ, IL-12, IL-2) and GM-CSF were revealed, as well as decrease of initially high levels of IL-10, like as lowered levels of IL-4 and IL-13. In cases of partial tumor regression, the levels of IFNα, IL-12, IL-2 and GM-CSF were decreased against initial values, and in the course of treatment they fluctuated within normal reference values. Cancellation of the therapy was followed by increase in IL-4 and IL-13 levels. Hence, the local rIFNα therapy is effective in controlling aggressive recurrent respiratory papillomatosis. Initial increase in TNFα and IL-4/IFNγ ratios in laryngeal secretions may be considered as favorable predictor of anticipated therapy, whereas increased levels of IFNα, IL-2 and IL-12 together with decrease (normalization) of IL-4/IFNγ ratio may reflect the efficiency of the treatment performed.
format	article
author	M. Plouzhnikov E. Katinas M. Ryabova S. Karpishenko K. Syssoev A. Chukhlovin A. Totolian
author_facet	M. Plouzhnikov E. Katinas M. Ryabova S. Karpishenko K. Syssoev A. Chukhlovin A. Totolian
author_sort	M. Plouzhnikov
title	LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
title_short	LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
title_full	LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
title_fullStr	LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
title_full_unstemmed	LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
title_sort	local application of recombinant interferon-alfa2 for treatment of recurrent respiratory papillomatosis
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/198ebee8cdc94eaf97af1418eb10420f
work_keys_str_mv	AT mplouzhnikov localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis AT ekatinas localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis AT mryabova localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis AT skarpishenko localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis AT ksyssoev localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis AT achukhlovin localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis AT atotolian localapplicationofrecombinantinterferonalfa2fortreatmentofrecurrentrespiratorypapillomatosis
_version_	1718422465970962432

LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS

Ejemplares similares